HOUSTON -- (October 18, 2007) --
Can Botox®, used early, help spinal cord injury patients who have an overactive bladder?
Dr. Christopher Smith, assistant professor of
urology at Baylor College of Medicine in Houston, hopes a federally
funded study conducted in conjunction with Memorial Hermann/The
Institute for Rehabilitation and Research in Houston, will answer the
question. BCM is one of 10 sites participating in the national study.
Spinal cord injuries from a variety of accidents affect approximately 250,000 Americans.
“Patients with spinal cord injury often develop a urological
dysfunction known as detrusor-sphincter dyssynergia, a condition
thought to contribute significantly to the development of bladder
overactivity, obstructed voiding patterns, and renal Impairment,”
Smith said. “We speculate that injecting Botox® into the
urethral sphincter shortly after spinal cord injury will prevent these
conditions from evolving.”
Sphincter dyssynergia causes a lack of coordination between the
bladder and the sphincter when a person voids. This lack of
coordination can increase bladder storage pressure and impair urinary
drainage from the kidneys, in some cases leading to permanent kidney
damage.
“In order for this process to work, the bladder and the
sphincter need to act in a coordinated fashion,” Smith said.
“The sphincter muscle should relax when the bladder contracts so
that urine can flow normally through the lower urinary tract.”
Botox®
is a commercial preparation of botulinum toxin A that works by
preventing nerve impulses from reaching the muscle. In this study,
Botox® will be injected into the urethral sphincter six weeks after
Spinal Cord Injury to relax the muscle and coordinate its action with
the bladder.
“We have never looked at using Botox® early after spinal
cord injury,” Smith said. “If we find that bladder
overactivity is driven by sphincter dysfunction, we can use Botox®
to reduce complications associated with detrusor-sphincter
dyssynergia.”
Those interested in taking part in this study can contact Sebrina Tello at stello@bcm.edu
or 713-798-8106. BCM is recruiting 167 patients. The study will be
funded by the National Institute of Neurological Disorders and Stroke.
For more information on this trial, visit http://www.bcm.edu/urology/?PMID=4989.